National Cancer Institute support for targeted alpha-emitter therapy
Authors:
- 11 August 2021
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 49 (1) , 64-72
Abstract
Background Radiopharmaceutical targeted therapy (RPT) has been studied for decades; however, recent clinical trials demonstrating efficacy have helped renewed interest in the modality. Methods This article reviews National Cancer Institute (NCI)’s support of RPT through communication via workshops and interest groups, through funding extramural programs in academia and small business, and through intramural research, including preclinical and clinical studies. Results NCI has co-organized workshops and organized interest groups on RPT and RPT dosimetry to encourage the community and facilitate rigorous preclinical and clinical studies. NCI has been supporting RPT research through various mechanisms. Research has been funded through peer-reviewed NCI Research and Program Grants (RPG) and NCI Small Business Innovation Research (SBIR) Development Center, which funds small business-initiated projects, some of which have led to clinical trials. The NCI Cancer Therapy Evaluation Program (CTEP)’s Radiopharmaceutical Development Initiative supports RPT in NCI-funded clinical trials, including Imaging and Radiation Oncology Core (IROC) expertise in imaging QA and dosimetry procedures. Preclinical targeted a-emitter therapy (TAT) research at the NCI’s intramural program is ongoing, building on foundational work dating back to the 1980s. Ongoing “bench-to-bedside” efforts leverage the unique infrastructure of the National Institutes of Health’s (NIH) Clinical Center. Conclusion Given the great potential of RPT, our goal is to continue to encourage its development that will generate the high-quality evidence needed to bring this multidisciplinary treatment to patients.Keywords
All Related Versions
This publication has 30 references indexed in Scilit:
- Dose Escalation and Dosimetry of First-in-Human α Radioimmunotherapy with 212Pb-TCMC-TrastuzumabJournal of Nuclear Medicine, 2014
- Targeted Radionuclide Therapy: Proceedings of a Joint Workshop Hosted by the National Cancer Institute and the Society of Nuclear Medicine and Molecular ImagingJournal of Nuclear Medicine, 2014
- 90Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent TrialJournal of Clinical Oncology, 2013
- A randomized study comparing yttrium‐90 ibritumomab tiuxetan (Zevalin) and high‐dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphomaCancer, 2012
- Anti–Glypican 3 Antibody as a Potential Antitumor Agent for Human Liver CancerCancer Research, 2008
- Multicenter Phase II Clinical Study of Iodine-131–Rituximab Radioimmunotherapy in Relapsed or Refractory Indolent Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2006
- 212Bismuth Linked to an Antipancreatic Carcinoma Antibody: Model for Alpha-Particle-Emitter RadioimmunotherapyJNCI: Journal of the National Cancer Institute, 1988
- Radioimmunodetection of Cutaneous T-Cell Lymphoma with111In-Labeled T101 Monoclonal AntibodyNew England Journal of Medicine, 1986
- Synthesis of 1-(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labeling and tumor-imaging studiesInorganic Chemistry, 1986
- Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy.Proceedings of the National Academy of Sciences, 1986